Long‐term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e‐antigen seroclearance

James Fung, Ka‐Shing Cheung, Danny Ka‐Ho Wong, Lung‐Yi Mak, Wai‐Pan To, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen – 13 March 2018 – The significance of hepatitis B e‐antigen (HBeAg) seroclearance (ESC) in the long term is not well defined. The current study aimed to determine the clinical outcomes, the factors and predictive scores for hepatocellular carcinoma (HCC), and hepatitis B surface antigen (HBsAg) seroclearance of a large cohort of patients undergoing ESC. Patients with documented ESC were followed up 3‐ to 6‐monthly.

The hepatic BMAL1/AKT/lipogenesis axis protects against alcoholic liver disease in mice via promoting PPARα pathway

Deqiang Zhang, Xin Tong, Bradley B. Nelson, Ethan Jin, Julian Sit, Nicholas Charney, Meichan Yang, M. Bishr Omary, Lei Yin – 13 March 2018 – Alcohol liver disease (ALD) is one of the major chronic liver diseases worldwide, ranging from fatty liver, alcoholic hepatitis, cirrhosis, and potentially, hepatocellular carcinoma. Epidemiological studies suggest a potential link between ALD and impaired circadian rhythms, but the role of hepatic circadian proteins in the pathogenesis of ALD remains unknown.

Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C

Narayan Ramamurthy, Emanuele Marchi, M. Azim Ansari, Vincent Pedergnana, Angela Mclean, Emma Hudson, STOP HCV consortium, Rory Bowden, Chris C.A. Spencer, Eleanor Barnes, Paul Klenerman – 13 March 2018 – New directly acting antivirals (DAAs) provide very high cure rates in most patients infected by hepatitis C virus (HCV). However, some patient groups have been relatively harder to treat, including those with cirrhosis or infected with HCV genotype 3.

CAAT/enhancer binding protein–homologous protein deficiency attenuates liver ischemia/reperfusion injury in mice

Seidai Wada, Etsuro Hatano, Tomoaki Yoh, Naohiko Nakamura, Yukihiro Okuda, Masayuki Okuno, Yosuke Kasai, Keiko Iwaisako, Satoru Seo, Kojiro Taura, Shinji Uemoto – 10 March 2018 – Ischemia/reperfusion injury (IRI) is one of the main causes of liver dysfunction after liver surgery. Involvement of endoplasmic reticulum (ER) stress in various diseases has been demonstrated, and CAAT/enhancer binding protein–homologous protein (CHOP) is a transcriptional regulator that is induced by ER stress. It is also a key regulator of ER stress‐mediated apoptosis.

The molecular adsorbent recirculating system in posthepatectomy liver failure: Results from a prospective phase I study

Stefan Gilg, Ernesto Sparrelid, Lars Saraste, Greg Nowak, Staffan Wahlin, Cecilia Strömberg, Lars Lundell, Bengt Isaksson – 8 March 2018 – Posthepatectomy liver failure (PHLF) represents the single most important cause of postoperative mortality after major liver resection, yet no effective treatment option is available. Extracorporeal liver support devices might be helpful, but systematic studies are lacking. Accordingly, we aimed to assess the safety and feasibility of the Molecular Adsorbent Recirculating System (MARS) in patients with PHLF.

LiverLearning®: 2018 Webinar: Surgical Risk in the Portal Hypertensive Patient

The webinar will focus on the best practices and the underlying evidence in terms of surgical management of the portal hypertensive patient. A practical approach will be outlined whereby patient risk, assessment, and management will be discussed. This is an essential and daily part  of practice for hepatologists and this  webinar will update and educate as to current management.Brett E. Fortune (Moderator) Brett E. Fortune, MD, MSc, is a transplant hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr.

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

Margo J.H. van Campenhout, Florian van Bömmel, Maria Pfefferkorn, Janett Fischer, Danilo Deichsel, André Boonstra, Anneke J. van Vuuren, Thomas Berg, Bettina E. Hansen, Harry L.A. Janssen – 7 March 2018 – Hepatitis B virus (HBV) RNA in serum is a novel biomarker for intrahepatic HBV replication and treatment response. For its proper use, it is essential to identify factors influencing serum HBV RNA level.

Subscribe to